Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives

13 Jun 2019

Abstract excerpt

Clinical Practice Points•Several ROS1 inhibitors have been developed that exhibit various potency against secondary resistance ROS1 mutations.•Despite in vitro efficacy against G2032R-mutated ROS1-rearranged non–small-cell lung cancer cell lines, cabozantinib treatment failed in our patient.•Discrepancies between in silico predictions, in vitro data, and clinical outcomes are discussed based on our patient’s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31395437
DOI: 10.1016/j.cllc.2019.06.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current PerspectivesPMID 31395437Read ↗

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsSemantic proximity Read ↗

Molecular Changes Associated with Acquired Resistance to Crizotinib in <i>ROS1</i> -Rearranged Non–Small Cell Lung CancerSemantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted TherapiesSemantic proximity Read ↗

ROS1-rearranged Non-small Cell Lung Cancer.Semantic proximity Read ↗

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial.Semantic proximity Read ↗

Importance of ROS1 fene fusions in non-small cell lung cancerSemantic proximity Read ↗

Progress of non-small-cell lung cancer with ROS1 rearrangementSemantic proximity Read ↗

Acquired ROS1 Intragenic Rearrangements as a Resistance Mechanism in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Series.Semantic proximity Read ↗

ROS1 Targeted Therapies: Current Status.Semantic proximity Read ↗

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.Semantic proximity Read ↗

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.